Biotechnology company focused on targeted kinase inhibitors
1 AI-extracted insight from 1 source — podcasts, YouTube channels, and X/Twitter accounts.
Based on 1 scored insight about Tyra Biosciences.
The 1 sources with the most insights about Tyra Biosciences on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Maintains a healthy cash position with little debt and upcoming clinical trial data catalysts expected in the first and second halves of the year.
Maintains a healthy cash position with little debt and upcoming clinical trial data catalysts expected in the first and second halves of the year.
Other assets that creators frequently mention in the same content as Tyra Biosciences.
The most active sources covering Tyra Biosciences (TYRA) on Kazuha are @realmartinshkreli. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 1 AI-extracted insight about Tyra Biosciences (TYRA) from 1 different source. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering Tyra Biosciences (TYRA) most frequently also discuss INTC, MU, 228A, RGTI, QBTS. See the "Discussed alongside" section above for full asset pages.